Rilonacept

drugbox
IUPAC_name = n/a


CAS_number =
ATC_prefix = L04
ATC_suffix = AC04
PubChem =
DrugBank =

molecular_weight =
bioavailability =
metabolism =
elimination_half-life =
excretion =
pregnancy_US = C
legal_UK =
legal_US = Rx-only
legal_status =
routes_of_administration = Subcutaneous
licence_US =Arcalyst

Rilonacept (marketed under the tradename Arcalyst), is a dimeric fusion protein for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). It was given an "Orphan Drug" status by the United States Food and Drug Administration.

It was approved by the FDA on February 2008. [cite web |url=http://www.drugs.com/newdrugs/fda-approves-arcalyst-new-orphan-cryopyrin-associated-periodic-syndromes-caps-876.html |title=Drugs.com, FDA Approves Arcalyst - New Orphan Drug for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) |accessdate=2008-03-15 |format= |work= ]

References

External links

* [http://www.regeneron.com/ Regeneron Pharmaceuticals home page]